Ask HopeStage to review this study with me
Study ID: NCT04722666. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT04722666
MIJ821 for depression
This study was terminated in the United States, in Canada, in Argentina, .... It is testing MIJ821 for depression.
Depression, SuicidalityOtherFrom 18 Years to 65 Years
Key information made simple
What is this study testing?
This study is testing whether Efficacy and Safety of MIJ821 may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Efficacy and Safety of MIJ821, attend study visits with the research team. The registry lists locations in Argentina, in Brazil, and in Canada.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a clinic, with sites including Novartis Investigative Site in Birmingham, Novartis Investigative Site in Farmington, and Novartis Investigative Site in Oakland Park. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results and safety concerns that need urgent care first. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: July 20, 2021
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- United States, Canada, Argentina, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04722666
- Official title
- Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicide prevention With Intent
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT04722666. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may help improve understanding of your condition.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Argentina.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring a mental health research question for people with depression. The research team can explain what participation involves. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Novartis Pharmaceuticals, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT02389712
16-week Comparative Effectiveness study of Lamotrigine vs. Fluoxetine for Depression in bipolarity
This study has public registry information. It focuses on bipolarity and currently lists study information in the United States.
TerminatedNCT05169710
Investigational Drug for depression
This study was terminated in the United States, in Canada, in Bulgaria, .... It is testing investigational Drug for depression.
TerminatedNCT05227209
Safety study of investigational Drug in depression
This study was terminated in the United States, in Bulgaria, and in Japan. It is testing investigational Drug for depression.